|
Testosterone and its esters are widely used for
androgen replacement therapy. Testosterone undergoes
5 alpha-reduction to dihydrotestosterone (DHT) in
the prostate and other tissues leading to potentially
undesirable consequences in adult males.
Trestolone or 7 alpha-Methyl-19-nortestosterone
(MENT) is a synthetic androgen that is ten times
as potent as testosterone. MENT is not 5-alpha reduced
to DHT. It inhibits gonadotrophin release, suppresses
testosterone and sperm production. Yet, MENT provides
adequate replacement therapy for most androgen-dependant
functions. MENT has a faster metabolic clearance
rate than testosterone and, in contrast
to testosterone, MENT does not bind to sex
hormone binding globulin (SHBG). MENT
remains capable of aromatization (to
7-alpha-methyl-estradiol)
preserving the benefits estrogen imparts
on male physiology.
The Population Council has investigated MENT
[specifically MENT Acetate (MENT Ac)] for long-term
clinical use for contraceptive purposes and hormone
replacement therapy. Initial trials suggest it may
be an ideal candidate since it is a non-5-alpha
reducible androgen and requires lower doses due
to its significantly increased potency over testosterone.
Various forms of MENT in human pharmaceutical
preparations and devices for contraception and hormone
therapy, specifically MENT Ac implant and MENT transdermal
gel and patch formulations, are currently under
clinical investigation. MENT is absorbed transdermally
up to three times the rate of testosterone - 17
methyl testosterone and 17-α methyl testosterone.
MENT, as a transdermal and/or intramuscular preparation,
will have application in a wide range of indications
beyond androgen replacement therapy and contraception,
including, without limitation, primary hypogonadism,
testicular failure, ASIH, baldness, sarcopenia,
loss of bone mass, muscle wasting and cachexia,
BPH, prostate cancer and of course, bodybuilding
and sports performance enhancement.
Trestolone acetate is the chemical
name of active ingredient in MENT. MENT
is a registered trademark of Population Council,
Inc. in the United States and/or other countries.
 |
|
Substance name
|
Trestolone acetate [USAN];
Orgasteron acetate; 7 alpha-Methyl-19-nortestosterone |
| Chemical name |
17 beta-hydroxy-7 alpha-methylestr-4-en-3-one
acetate |
| Systematic name |
IUPAC: [(7R,9S,14S,17S)-7,13-dimethyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]
acetate |
| CAS number |
6157-87-5; 3764-87-2 (base) |
| Merck Index Number |
|
| Molecular formula |
C21-H30-O3 |
| Molecular weight |
330.465 g/mol |
| Pregnancy category |
X |
| Legal status |
Illegal
(US); DEA Schedule III (US) |
| Routes of administration |
Transdermal, Intramuscular |
References
- Sundaram K, Numar K. 7alpha-methyl-19-nortestosterone
(MENT): the optimal androgen for male contraception
and replacement therapy. Int J Androl. 2000;23
Suppl 2:13-5.
- Anderson, Richard A., A. Michael Wallace,
Naveed Sattar, Narender Kumar, and Kalyan Sundaram.
“Evidence for tissue selectivity of the synthetic
androgen 7α-methyl-19-nortestosterone in hypogonadal
men,” Journal of Clinical Endocrinology and
Metabolism 88(6): 2784–2793.
- von Eckardstein, Sigrid, Gabriela Noe, Vivian
Brache, Eberhard Nieschlag, Horacio Croxatto,
Francisco Alvarez, Alfred Moo-Young, Irving
Sivin, Narender Kumar, Margaret Small, and Kalyan
Sundaram, Population Council International Committee
for Contraception Research. “A clinical trial
of 7-α-methyl-19-nortestosterone implants for
possible use as a long-acting contraceptive
for men,” Journal of Clinical Endocrinology
and Metabolism 88(11): 5232–5239.
Visit Our Forums to Learn More About Anabolic Steroids
|